Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Short-Term Clinical Outcomes of Small.

Advertisements

From: Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients: A Three-Dimensional Volumetric Intravascular Ultrasound.

Nat. Rev. Cardiol. doi: /nrcardio

DRug Eluting Bbsorbable Metal Scaffold (DREAMS)

Figure 1 Flow diagram of systematic review

Multivessel PCI: Pearls of Wisdom (?) for Success

Long-term coronary arterial response to biodegradable polymer biolimus-eluting stents in comparison with durable polymer sirolimus-eluting stents and.

Retrospective Study of First-Generation Drug-Eluting Stents, Second-Generation Drug- Eluting Stents and Non-Drug Eluting Stent Methods in the Treatment.

Alexandra Lansky, MD Yale School of Medicine

Nat. Rev. Cardiol. doi: /nrcardio

Median target vessel revascularization rates per 1000 patient-years of follow-up with bare metal stents (BMS) and first- and second-generation drug-eluting.

Greg L. Kaluza, MD, PhD, FACC Cardiovascular Research Foundation

Update on the BioMatrix Program

Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support.

Elixir Medical Novolimus Elution from A Biodegradable Polymer

Second Generation DES Associated with Less Late and Very Late Stent Thrombosis Compared to First Generation DES Donald E. Cutlip, MD Beth Israel Deaconess.

Circ Cardiovasc Interv

Comparison of prevalence of uncovered struts between ZES and EES groups. Comparison of prevalence of uncovered struts between ZES and EES groups. Scatter plot.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Pathological specimens showing the most common reasons for bioprosthetic valve failure Figure 2 | Pathological specimens showing the most common.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Gregg W. Stone, MD Columbia University Medical Center

Figure 1 Anatomy of the femoral artery

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 2 Size categorization of airborne pollutants

Nat. Rev. Cardiol. doi: /nrcardio

Primary endpoint at 1 year

Nat. Rev. Cardiol. doi: /nrcardio

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.

Figure 1 Decision tree integrating the assessment,

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Milestones in coronary angioplasty

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

ENDEAVOR II Five-Year Clinical Follow-up

Figure 5 Bioresorbable vascular scaffold apposition and strut coverage

NEW GENERATION STENT COBALT-CHROMIUM SIROLIMUS ELUTING STENT.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Electrocardiogram patterns associated with Brugada syndrome

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

(p for non-inferiority < 0.001)

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Drug-eluting coronary stent market overview

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.151 Figure 3 Comparison of the strut thickness of different categories of stent Figure 3 | Comparison of the strut thickness of different categories of stent. The strut thicknesses of clinically available bioresorbable vascular scaffolds are depicted, along with the most commonly used metallic drug-eluting stents. Strut thickness of bioresorbable non-metallic is substantially larger than that in currently available durable metallic stents and biodegradable polymer-coated metallic stents. BES, biolimus-eluting stent; CoCr, cobalt–chromium; CoNi, cobalt–nickel; EES, everolimus-eluting stent; NOV, novolimus-eluting stent; PLLA,poly-l-lactic acid; Pt, platinum; PtCr, platinum–chromium; PtIr, platinum–iridium; SES, sirolimus-eluting stent; ZES, zotarolimus-eluting stent. Indolfi, C. et al. (2016) Bioresorbable vascular scaffolds — basic concepts and clinical outcome Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.151